Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02860585

Acronym

BREAST-HDCT

Enrollment

235

Registered

2016-08-09

Start date

2013-09-27

Completion date

2016-02-29

Last updated

2017-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Metastatic breast cancer, high-dose chemotherapy, autologous haematopoietic progenitor cell transplantation

Brief summary

The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\>18 years * Metastatic breast Cancer * Treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation between 2003 and 2012

Exclusion criteria

* Lack of follow-up data

Design outcomes

Primary

Measure	Time frame
Overall Survival according to Immunohistochemical subtypes .	8 years

Secondary

Measure	Time frame
Progression free Survival according to Immunohistochemical subtypes .	8 years

Countries

France

Outcome results